Nuvelo To Consider In-Licensing Deals In Wake Of Negative Alfimeprase Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm halts enrollment of trials of the thrombolytic pending further review by outside experts and monitoring board.
You may also be interested in...
Nuvelo Discontinues Factor VIIa Inhibitor To Focus On Alfimeprase
As part of the realignment, Nuvelo will cut its work force by 30 percent and reduce annual expenses by $15 million.
Nuvelo Discontinues Factor VIIa Inhibitor To Focus On Alfimeprase
As part of the realignment, Nuvelo will cut its work force by 30 percent and reduce annual expenses by $15 million.
For Now, Nuvelo Will Go It Alone On Thrombolytic Alfimeprase
Development of the stalled anti-clotting agent resumes as partner Bayer pulls out of the collaboration.